Autophagy
TL;DR
Autophagy (Greek: “self-eating”) is the cell’s lysosome-dependent degradation pathway that clears damaged organelles, misfolded proteins, and intracellular pathogens. Three types exist: macroautophagy (main form, double-membrane autophagosome), microautophagy (direct lysosomal engulfment), and chaperone-mediated autophagy (CMA, via LAMP-2A). Autophagy declines with age; restoring it is one of the most validated longevity interventions across species. Primary triggers: mTORC1 inhibition (fasting, rapamycin) and AMPK activation (exercise, metformin). The 24–72 hour fast is the canonical autophagy window; peak induction at 48–72 hours.
Why It Matters for Vitals
Autophagy underpins cellular quality control — when it declines, damaged mitochondria accumulate, protein aggregates form, and senescent cells drive systemic inflammation. For Vitals users:
- HRV connection: vagal tone supports autophagy via the cholinergic anti-inflammatory pathway; high HRV reflects autonomic state that supports autophagic capacity
- Body composition: Retatrutide’s caloric restriction may produce a chronic mild-fasted state → modest persistent elevation in basal autophagy
- Stack logic: Urolithin A clears damaged mitochondria via mitophagy; Rapamycin activates broad autophagy via mTORC1; exercise activates AMPK-driven autophagy — these are complementary entry points to the same system
- Wearables: no direct wearable signal for autophagy; indirect proxy is HRV trend (parasympathetic = autophagic capacity indicator)
Mechanism Summary
Primary Trigger: mTORC1 Inhibition
mTORC1 phosphorylates and inhibits ULK1 (autophagy initiation complex). Under nutrient-rich conditions, autophagy is blocked. During fasting, mTORC1 activity drops → ULK1 de-repressed → autophagosome formation begins.
Secondary Trigger: AMPK Activation
AMPK activates ULK1 directly (phosphorylation at Ser317, Ser777) and inhibits mTORC1 → convergent autophagy activation. Exercise activates AMPK via increased AMP:ATP ratio and CAMKK2 calcium signaling.
Autophagy Timeline (Fasting)
| Time | Autophagy Phase |
|---|---|
| 0–14h | Postprandial; mTORC1 active; basal autophagy only |
| ~14–16h | Meaningful autophagy begins in liver |
| ~24h | Significant autophagy in most tissues; autophagosome formation peaks in liver |
| 48–72h | Peak autophagy window; mTORC1 maximally suppressed; growth hormone elevated 2–5× |
| 72h+ | Diminishing returns; mTOR rebound as amino acids recycle; muscle protein breakdown risk rises |
Key principle: autophagy is tissue-specific. Liver peaks earlier (12–24h) than muscle (24–48h). Brain requires longer fasting (48h+) due to blood-brain barrier selective amino acid delivery.
Types of Autophagy
| Type | Mechanism | Key Markers |
|---|---|---|
| Macroautophagy | Double-membrane autophagosome engulfs cargo | LC3-II, Beclin-1, ATG proteins |
| Microautophagy | Lysosomal membrane invaginates directly | ESCRT-mediated |
| CMA (Chaperone-Mediated) | Hsc70 recognizes KFERQ motif → delivered via LAMP-2A | LAMP-2A declines with age |
Key Pharmacological Inducers
| Inducer | Mechanism | Evidence Grade | Vitals Relevance |
|---|---|---|---|
| Rapamycin | Direct mTORC1 inhibitor → de-represses ULK1 | A | FDA-approved; longevity data in mice; immunosuppression limits use |
| Urolithin A | Direct PINK1/Parkin mitophagy inducer | A | Best-evidenced mitophagy-specific human compound; 500–1000 mg/day |
| Spermidine | Inhibits eIF5A hypusination → ATF4 → autophagy genes | B | Found in aged cheese, soy, mushrooms; 1–3 mg/day supplement |
| Metformin | Activates AMPK via LKB1 | B | Safe, widely used; TAME trial ongoing |
| Berberine | Potent AMPK activator | B | Comparable to metformin; GI side effects common |
| Exercise | AMPK activation + mTORC1 inhibition | A | Post-exercise window: 4–24h of elevated autophagic flux |
Autophagy and Key Vitals Compounds
Retatrutide (GLP-1/GCGR Agonist)
- GLP-1R → AMPK activation + mTOR suppression in hepatocytes → hepatic autophagy (Grade B, inferred from liraglutide/semaglutide data)
- GCGR agonism → additional AMPK activation in liver during caloric deficit (Grade C)
- Retatrutide’s caloric restriction from appetite suppression may produce chronic mild basal autophagy elevation — low-level “fasting mimicry” effect
- No direct Retatrutide autophagy studies exist
GHK-Cu
- Promotes autophagic flux in fibroblast culture under oxidative stress conditions
- Likely indirect (via reduced oxidative stress) rather than direct autophagy gene regulation
- Grade C — no direct human data
- May synergize with urolithin A (mitophagy) and Retatrutide (hepatic autophagy) as a broader autophagy support milieu
Relationship to Existing Mechanism Notes
- Mitophagy — selective autophagy of mitochondria; the autophagy subtypes are distinct but complementary
- Exercise Mimetics — overlaps via AMPK/mTOR axis
- Rapamycin — mTORC1 inhibitor and broad autophagy activator
- Urolithin A — canonical mitophagy inducer (PINK1/Parkin pathway)
Related Notes
- HRV — HRV as non-invasive proxy for autonomic health supporting autophagic capacity
- Rapamycin — mTORC1 inhibitor hub
- Urolithin A — mitophagy-specific inducer
- GHK-Cu — copper tripeptide; autophagy-modulating properties
- Retatrutide — GLP-1/GCGR; fasting-mimicry autophagy hypothesis
- Peptides MOC — peptide/compound index